Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Binghao Zhao,Huanzhang Li,Yu Xia,Yaning Wang,Yuekun Wang,Yixin Shi,Hao Xing,Tian Qu,Yu Wang,Wenbin Ma

DOI: https://doi.org/10.1186/s13045-022-01364-7

2022-10-27

Abstract:Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory role in the T cell response, has been highlighted as a novel potential target for cancer immunotherapy. B7-H3 has been shown to play an inhibitory role in T cell activation and proliferation, participate in tumor immune evasion and influence both the immune response and tumor behavior through different signaling pathways. B7-H3 expression has been found to be aberrantly upregulated in many different cancer types, and an association between B7-H3 expression and poor prognosis has been established. Immunotherapy targeting B7-H3 through different approaches has been developing rapidly, and many ongoing clinical trials are exploring the safety and efficacy profiles of these therapies in cancer. In this review, we summarize the emerging research on the function and underlying pathways of B7-H3, the expression and roles of B7-H3 in different cancer types, and the advances in B7-H3-targeted therapy. Considering different tumor microenvironment characteristics and results from preclinical models to clinical practice, the research indicates that B7-H3 is a promising target for future immunotherapy, which might eventually contribute to an improvement in cancer immunotherapy that will benefit patients.

oncology,hematology

What problem does this paper attempt to address?

The problem this paper attempts to address is the role of B7-H3 in cancer immunotherapy and its potential mechanisms. Specifically, the authors aim to comprehensively review the functions of B7-H3, its expression and role in different types of cancer, and the progress of immunotherapy targeting B7-H3. The main focus points of the paper are as follows:

1. **Functions and signaling pathways of B7-H3**: The paper summarizes the role of B7-H3 in immune regulation, particularly its inhibitory effect on T cell activation and proliferation, and its involvement in tumor immune evasion mechanisms.

2. **Expression and role of B7-H3 in different types of cancer**: The authors explore the abnormally high expression of B7-H3 in various types of cancer and discuss the relationship between this expression and poor prognosis.

3. **Receptors of B7-H3**: The paper discusses potential receptors of B7-H3, including TLT-2, IL20RA, and PLA2R1, and analyzes the functions of these receptors in different cell types and their impact on the biological effects of B7-H3.

4. **Role of B7-H3 in malignant behaviors**:
- **Cancer cell proliferation**: B7-H3 promotes cancer cell proliferation by activating signaling pathways such as PI3K and MEK.
- **Cancer cell metabolic dysregulation**: B7-H3 promotes glycolysis in cancer cells through mechanisms such as stabilizing HIF-1α and activating downstream glycolytic enzymes.
- **Cancer cell invasion and metastasis**: B7-H3 promotes cancer cell invasion and epithelial-mesenchymal transition (EMT) by activating signaling pathways such as JAK2/STAT3.
- **Anti-apoptotic activity**: B7-H3 inhibits cancer cell apoptosis through pathways such as JAK2/STAT3.
- **Therapeutic resistance**: B7-H3 promotes cancer cell resistance to chemotherapy and radiotherapy by altering glucose metabolism and increasing apoptosis resistance.

5. **Clinical trial progress of B7-H3 targeted therapy**: The paper summarizes the ongoing clinical trials targeting B7-H3, evaluating the safety and efficacy of these therapies.

Through the above content, the authors aim to provide a theoretical basis and clinical guidance for future B7-H3-based immunotherapy.